Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration
This publication has 25 references indexed in Scilit:
- Artificial Intelligence in Cardiovascular Clinical TrialsJACC, 2024
- Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical TrialJAMA Cardiology, 2024
- Innovation in Event Adjudication—Human vs MachineJAMA Cardiology, 2024
- The Future of Clinical TrialsJAMA, 2023
- Natural Language Processing for Adjudication of Heart Failure in the Electronic Health RecordJACC: Heart Failure, 2023
- Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced TrialJACC: Heart Failure, 2023
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITJACC, 2021
- Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular DiseaseJAMA, 2021
- Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research ConsortiumEuropean Journal of Heart Failure, 2020
- Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016JAMA Internal Medicine, 2018